Patents by Inventor Raymond J. Bergeron, Jr.
Raymond J. Bergeron, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20140343110Abstract: Macular degeneration, closed head injury, stroke, irritable bowel disease, and reperfusion injury are all associated with biological injury due to reactive oxygen species, probably due to focal iron overload in many instances. The present invention provides methods and pharmaceutical compositions for treating these diseases and conditions using desferrithiocin analogs of Formula (I). In certain embodiments, the analogs include a polyether moiety at the 4?-position of the phenyl ring of the compound.Type: ApplicationFiled: December 14, 2012Publication date: November 20, 2014Applicant: University of Florida Research Foundation, Inc.Inventor: Raymond J. Bergeron, JR.
-
Publication number: 20140323534Abstract: Macular degeneration, closed head injury, stroke, irritable bowel disease, and reperfusion injury are all associated with biological injury due to reactive oxygen species, probably due to focal iron overload in many instances. The present invention provides methods and pharmaceutical compositions for treating these diseases and conditions using desferrithiocin analogs of Formula (I). In certain embodiments, the analogs include a polyether moiety at the 3?-position of the phenyl ring of the compound. Formula (I).Type: ApplicationFiled: December 14, 2012Publication date: October 30, 2014Applicant: University of Florida Research Foundation, Inc.Inventor: Raymond J. Bergeron, JR.
-
Patent number: 8834890Abstract: An immunogenic composition comprising a siderophore covalently linked to a pharmaceutically acceptable carrier molecule wherein the antigenicity of the siderophore moiety is sufficient to stimulate an immunologic response to the siderophore when the composition is circulating in the bloodstream of a human or non-human animal and vaccine.Type: GrantFiled: April 20, 2010Date of Patent: September 16, 2014Assignee: University of Florida Research Foundation, Inc.Inventor: Raymond J. Bergeron, Jr.
-
Publication number: 20140235680Abstract: Compounds represented by structural formulas described herein, such as Structural Formula (I): or a pharmaceutically acceptable salt thereof are useful in treating conditions such as metal overload, oxidative stress, and neoplastic and preneoplastic conditions.Type: ApplicationFiled: April 29, 2014Publication date: August 21, 2014Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.Inventor: Raymond J. Bergeron, JR.
-
Patent number: 8722899Abstract: Compounds represented by structural formulas described herein, such as Structural Formula (I): or a pharmaceutically acceptable salt thereof are useful in treating conditions such as metal overload, oxidative stress, and neoplastic and preneoplastic conditions.Type: GrantFiled: September 28, 2012Date of Patent: May 13, 2014Assignee: University of Florida Research Foundation, Inc.Inventor: Raymond J. Bergeron, Jr.
-
Patent number: 8604216Abstract: Compounds represented by structural formulas such as Structural Formula (I): are highly efficient in clearing excess iron from an organism. The invention also discloses methods of treating conditions such as metal overload, oxidative stress, and neoplastic and preneoplastic conditions.Type: GrantFiled: March 2, 2006Date of Patent: December 10, 2013Assignee: University of Florida Research Foundation, Inc.Inventor: Raymond J. Bergeron, Jr.
-
Publication number: 20130030028Abstract: Compounds represented by structural formulas described herein, such as Structural Formula (I): or a pharmaceutically acceptable salt thereof are useful in treating conditions such as metal overload, oxidative stress, and neoplastic and preneoplastic conditions.Type: ApplicationFiled: September 28, 2012Publication date: January 31, 2013Applicant: University of Florida Research Foundation, Inc.Inventor: Raymond J. Bergeron, Jr.
-
Patent number: 8324397Abstract: A relatively non-toxic desazadesferrithiocin analog having the formula (I): wherein: R1, R2, R4 and R5 may be the same or different and may be H, straight or branched chain alkyl having up to 14 carbon atoms, e.g., methyl, ethyl, propyl and butyl, or arylalkyl wherein the aryl portion is hydrocarbyl and the alkyl portion is straight or branched chain, the arylalkyl group having up to 14 carbon atoms, R2 optionally being alkoxy having up to 14 carbon atoms; R3 is [(CH2)n—O]x—[(CH2)n—O]y-alkyl; n is, independently, an integer from 1 to 8; x is an integer from 1 to 8; y is an integer from O to 8, and R3O may occupy any position on the phenyl ring except the 4-position, or a salt, hydrate or solvate thereof; and methods and compositions for treating the effects of trivalent metal, i.e., iron, overload.Type: GrantFiled: March 14, 2008Date of Patent: December 4, 2012Assignee: University of Florida Research Foundation, Inc.Inventor: Raymond J. Bergeron, Jr.
-
Patent number: 8278458Abstract: Compounds represented by structural formulas described herein, such as Structural Formula (I): or a pharmaceutically acceptable salt thereof are useful in treating conditions such as metal overload, oxidative stress, and neoplastic and preneoplastic conditions.Type: GrantFiled: October 4, 2007Date of Patent: October 2, 2012Assignees: University of Florida Research Foundation, Inc., University of Florida, The United States of America as Represented by the National Institutes of Health (NIH), The United States of America as Represented by the Department of Health and Human ServicesInventor: Raymond J. Bergeron, Jr.
-
Publication number: 20120184586Abstract: Desferrithiocin analogues represents by the structural formulae described here, such as formula (I), are useful in treating conditions such as metal overload (e.g., iron overload from transfusion therapy), oxidative stress, and neoplastic and preneoplastic conditions.Type: ApplicationFiled: August 25, 2010Publication date: July 19, 2012Applicant: University of Florida Research Foundation, Inc.Inventor: Raymond J. Bergeron, JR.
-
Publication number: 20120052087Abstract: An immunogenic composition comprising a siderophore covalently linked to a pharmaceutically acceptable carrier molecule wherein the antigenicity of the siderophore moiety is sufficient to stimulate an immuno-logic response to the siderophore when the composition is circulating in the bloodstream of a human or non-human animal and vaccine.Type: ApplicationFiled: April 20, 2010Publication date: March 1, 2012Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.Inventor: Raymond J. Bergeron, JR.
-
Patent number: 7879886Abstract: Composition, article of manufacture for and method of treating malaria in a human having an infestation of Plasmodium protozoans are described. The method comprises administering a therapeutically-effective amount of a compound of formula (I) or (IV), i.e. sufficient quantity to reduce the population of Plasmodium. The composition of the invention is a compound of formula (I) or (IV) with a pharmaceutical excipient. The article of manufacture is the composition in combination with labeling for treating malaria. The substituents are detailed in the specification.Type: GrantFiled: October 17, 2006Date of Patent: February 1, 2011Assignee: University of Florida Research Foundation, Inc.Inventor: Raymond J. Bergeron, Jr.
-
Publication number: 20100137346Abstract: A pharmaceutical composition comprising a non-toxic effective amount of an actinide decorporation agent and a pharmaceutically acceptable carrier therefore, the actinide decorporation agent comprising a hexacoordinate desferrithiocin analogue capable of chelating an actinide in vivo and a method for removing an actinide from the tissue of a human or nonhuman mammal.Type: ApplicationFiled: December 12, 2007Publication date: June 3, 2010Applicant: University of Florida Research Foundation, Inc.Inventor: Raymond J. Bergeron, JR.
-
Publication number: 20100093812Abstract: A relatively non-toxic desazadesferrithiocin analog having the formula (I): wherein: R1, R2, R4 and R5 may be the same or different and may be H, straight or branched chain alkyl having up to 14 carbon atoms, e.g., methyl, ethyl, propyl and butyl, or arylalkyl wherein the aryl portion is hydrocarbyl and the alkyl portion is straight or branched chain, the arylalkyl group having up to 14 carbon atoms, R2 optionally being alkoxy having up to 14 carbon atoms; R3 is [(CH2)n—O]x—[(CH2)n—O]y-alkyl; n is, independently, an integer from 1 to 8; x is an integer from 1 to 8; y is an integer from O to 8, and R3O may occupy any position on the phenyl ring except the 4-position, or a salt, hydrate or solvate thereof; and methods and compositions for treating the effects of trivalent metal, i.e., iron, overload.Type: ApplicationFiled: March 14, 2008Publication date: April 15, 2010Applicant: University of Florida Research Foundation, Inc.Inventor: Raymond J. Bergeron, JR.
-
Patent number: 7691864Abstract: Pharmaceutical compositions for the treatment of hypertension comprising an effective anti-hypertensive amount of at least one compound in association with a pharmaceutically acceptable, substantially non-toxic carrier or excipient, the compound having one of the formulae (I), (II), (III) or (IV), and methods for the treatment of hypertension or effecting anti-hypertensive action which comprises administering to a patient requiring anti-hypertensive therapy or effect at least one of the above-described compounds.Type: GrantFiled: October 27, 2004Date of Patent: April 6, 2010Assignee: University of FloridaInventor: Raymond J. Bergeron, Jr.
-
Patent number: 7423182Abstract: An aminated polyamine having the formula: or its possible stereoisomers or a salt thereof with a pharmaceutically acceptable acid wherein: R1 and R4 may be the same or different and are alkyl, aryl, aryl alkyl or cycloalkyl, optionally having an alkyl chain interrupted by at least one etheric oxygen atom; R2 and R3 may be the same or different and are R1, R4 or H; N1, N2, N3 and N4 are nitrogen atoms capable of protonation at physiological pH's; ALK1, ALK2 AND ALK3 may be the same or different and are straight or branched chain alkylene bridging groups having 1 to 4 carbon atoms which effectively maintain a predetermined distance between the nitrogen atoms such that the polyamine upon uptake by the target cell, competitively functions in a manner wherein at least one of said bridging groups ALK1, ALK2 and ALK3 contains at least one —CH(NRH)— group which is not alpha- to either of the nitrogen atoms and R is H, alkyl, acyl or sulfonyl.Type: GrantFiled: November 3, 2004Date of Patent: September 9, 2008Assignee: University of FloridaInventor: Raymond J. Bergeron, Jr.
-
Patent number: 7144904Abstract: Composition, article of manufacture for and method of treating malaria in a human having an infestation of Plasmodium protozoans are described. The method comprises administering a therapeutically-effective amount of a compound of formula (I) or (IV), i.e. sufficient quantity to reduce the population of Plasmodium. The composition of the invention is a compound of formula (I) or (IV) with a pharmaceutical excipient. The article of manufacture is the composition in combination with labeling for treating malaria. The substituents are detailed in the specification.Type: GrantFiled: November 19, 2004Date of Patent: December 5, 2006Assignee: University of Florida Research Foundation, Inc.Inventor: Raymond J. Bergeron, Jr.
-
Patent number: 7094808Abstract: Polyamines having the formula: or a salt thereof with a pharmaceutically acceptable acid wherein: R1-R6 may be the same or different and are alkyl, aryl, aryl alkyl, cycloalkyl, optionally having an alkyl chain interrupted by at least one etheric oxygen atom, or hydrogen; N1, N2, N3 and N4 are nitrogen atoms capable of protonation at physiological pH's; a and b may be the same or different and are integers from 1 to 4; A, B and C may be the same or different and are bridging groups which effectively maintain the distance between the nitrogen atoms such that the polyamines: (i) are capable of uptake by a target cell upon administration thereof to a human or non-human animal; and (ii) upon uptake by the target cell, competitively bind via an electrostatic interaction between the positively charged nitrogen atoms to substantially the same biological counter-anions as the intracellular natural polyamines in the target cell; the polyamines, upon binding to the biological counter-anion in the cell, functioType: GrantFiled: September 4, 2002Date of Patent: August 22, 2006Assignee: University of Florida Research Foundation, Inc.Inventor: Raymond J. Bergeron, Jr.
-
Patent number: 6864270Abstract: Composition, article of manufacture for and method of treating malaria in a human having an infestation of Plasmodium protozoans are described. The method comprises administering a therapeutically-effective amount of a compound of formula (I) or (IV), i.e. sufficient quantity to reduce the population of Plasmodium. The composition of the invention is a compound of formula (I) or (IV) with a pharmaceutical excipient. The article of manufacture is the composition in combination with labeling for treating malaria. The substituents are detailed in the specification.Type: GrantFiled: August 8, 2002Date of Patent: March 8, 2005Assignee: University of Florida Research Foundation, Inc.Inventor: Raymond J. Bergeron, Jr.
-
Patent number: RE39132Abstract: Phenyl- and pyridyl-substituted thiazoline acid derivatives useful in diagnosing and treating pathological conditions associated with an excess of trivalent metals in humans and animals.Type: GrantFiled: October 17, 2001Date of Patent: June 13, 2006Assignee: University of Florida, Research Foundation, Inc.Inventor: Raymond J. Bergeron, Jr.